Peritoneal Dialysis in Patients with Refractory Congestive Heart Failure: Potential Prognostic Factors

2013 ◽  
Vol 35 (4) ◽  
pp. 285-294 ◽  
Author(s):  
Margarita Kunin ◽  
Michael Arad ◽  
Dganit Dinour ◽  
Dov Freimark ◽  
Eli J. Holtzman
2011 ◽  
Vol 80 (9) ◽  
pp. 970-977 ◽  
Author(s):  
Florence Sens ◽  
Anne-Marie Schott-Pethelaz ◽  
Michel Labeeuw ◽  
Cyrille Colin ◽  
Emmanuel Villar

1996 ◽  
Vol 27 (2) ◽  
pp. 358 ◽  
Author(s):  
Donna L. Hudson ◽  
Maurice E. Cohen ◽  
Rebecca J. Kanefield ◽  
Prakash C. Deedwania

2008 ◽  
Vol 28 (5) ◽  
pp. 509-517 ◽  
Author(s):  
Cécile Couchoud ◽  
Emilie Savoye ◽  
Luc Frimat ◽  
Jean-Philippe Ryckelynck ◽  
Ylana Chalem ◽  
...  

In France, the use of peritoneal dialysis (PD) as the first-choice treatment varies greatly between districts, as it is already known to do between countries. Baseline clinical factors associated with choice of first modality were analyzed in 10815 new end-stage renal disease patients in 59 districts. To describe practices at the district level, we used an agglomerative hierarchical classification, with proximity defined by a likelihood-ratio test that compared multivariate logistic regressions of the following factors: age, gender, diabetes, congestive heart failure, severe behavioral disorders, mobility, and employment. To propose a typology, each cluster of districts was described by a multivariate logistic regression. While populations starting PD in France, as elsewhere, are more likely to be young or employed, they are also more likely to be elderly or have congestive heart failure or severe behavioral disorders. Overall, 14% of patients start with PD, but this rate varies significantly across districts, from 0% to 45%. A specific combination of factors was associated with the first-choice modality in each group of districts. This study highlights the lack of consensual medical criteria for this choice and the likelihood that nonmedical factors may explain the observed differences. The high variability suggests that PD can be used in almost all clinical conditions. Accordingly, patient preference should play a more important role in the decision-making process.


1983 ◽  
Vol 3 (3) ◽  
pp. 130-131 ◽  
Author(s):  
Michael Robson ◽  
Arie Biro Boleswar ◽  
Knobel George Schai ◽  
Mordchai Ravid

Three patients with intractable congestive heart failure (CHF) resistant to all other therapy were treated for three, five and six months by continuous ambulatory peritoneal dialysis (CAPD). They lost eight to II kg in weight and had a marked improvement in symptoms of heart failure. Recurrent peritonitis precluded the continuation of CAPD and all three patients died within two weeks of stopping the treatment.


2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Qiuyuan Shao ◽  
Yangyang Xia ◽  
Min Zhao ◽  
Jing Liu ◽  
Qingyan Zhang ◽  
...  

Aims. To evaluate the effectiveness and safety of peritoneal dialysis (PD) in treating refractory congestive heart failure (RCHF) with cardiorenal syndrome (CRS).Methods. A total of 36 patients with RCHF were divided into type 2 CRS group (group A) and non-type 2 CRS group (group B) according to the patients’ clinical presentations and the ratio of serum urea to creatinine and urinary analyses in this prospective study. All patients were followed up till death or discontinuation of PD. Data were collected for analysis, including patient survival time on PD, technique failure, changes of heart function, and complications associated with PD treatment and hospitalization.Results. There were 27 deaths and 9 patients quitting PD program after a follow-up for 73 months with an average PD time of22.8±18.2months. A significant longer PD time was found in group B as compared with that in group A (29.0±19.4versus13.1±10.6months,p=0.003). Kaplan–Meier curves showed a higher survival probability in group B than that in group A (p<0.001). Multivariate regression demonstrated that type 2 CRS was an independent risk factor for short survival time on PD. The benefit of PD on the improvement of survival and LVEF was limited to group B patients, but absent from group A patients. The impairment of exercise tolerance indicated by NYHA classification was markedly improved by PD for both groups. The technique survival was high, and the hospital readmission was evidently decreased for both group A and group B patients.Conclusions. Our data suggest that PD is a safe and feasible palliative treatment for RCHF with type 2 CRS, though the long-term survival could not be expected for patients with the type 2 CRS. Registration ID Number isChiCTR1800015910.


2005 ◽  
Vol 20 (suppl_7) ◽  
pp. vii32-vii36 ◽  
Author(s):  
Lazaro Gotloib ◽  
Roberto Fudin ◽  
Michaela Yakubovich ◽  
Joerg Vienken

2009 ◽  
Vol 119 (12) ◽  
pp. 815-819
Author(s):  
Agnieszka Próchnicka ◽  
Anna Olszowska ◽  
Daniel Baczyński ◽  
Grzegorz Żelichowski ◽  
Zofia Wańkowicz

1966 ◽  
Vol 5 (12) ◽  
pp. 755-759 ◽  
Author(s):  
Stanley J. Stamm ◽  
Jack Doctor ◽  
Robert Rose ◽  
James Isbister ◽  
Robert Hickman

Sign in / Sign up

Export Citation Format

Share Document